Abstract:Key PointsAdvanced non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the world.Epidermal growth factor receptor (EGFR) is expressed in 50% of NSCLCs, and its expression is correlated with poor prognosis. These two factors make EGFR and its family members prime candidates for the development of targeted therapeutics.Two EGFR-targeting small-molecule inhibitors, gefitinib (Iressa: AstraZeneca, approved in May 2003) and erlotinib (Tarceva: OSI-Genentech, approved in November 2004) received fast-track approval from the US Food and Drug Administration as treatment for patients with advanced NSCLC who had failed to respond to conventional chemotherapy.Early clinical data showed that 10% of patients with NSCLC responded to gefitinib or erlotinib. Although infrequent, the speed and magnitude of clinical responses were unique, as was the fact that they were seen in specific subsets of cases (non-smokers, women, East Asians and patients with adenocarcinomas with bronchioloalveolar histology).Molecular analysis showed that in most instances, responders harboured specific mutations in the gene that encodes EGFR. Exon 19 mutations characterized by in-frame deletions of amino-acids 747–750 account for 45% of mutations, exon 21 mutations resulting in L858R substitutions account for 40–45% of mutations, and the remaining 10% of mutations involve exon 18 and 20.EGFR kinase domain mutations hyperactivate the kinase and confer a dependence on the mutated kinase for the survival of the NSCLC tumour cells.The treatment of sensitive cells with targeted therapeutics such as gefitinib and erlotinib seems to trigger a form of 'oncogenic shock', which is postulated to result from the differential decay of downstream signals leading to a temporary predominance of apoptotic signals.Acquired resistance to gefitinib and erlotinib might involve the recurrent mutation T790M which affects the gatekeeper residue in the catalytic domain of the kinase that weakens the interaction of the inhibitor with its target. Resistance can be overcome in vitro by irreversible inhibitors of EGFR

A Rare Epidermal Growth Factor Receptor G735R Mutation in Advanced Non-Small-Cell Lung Cancer with Poor Response to Gefitinib

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement

Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report.

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Lung Squamous Cell Carcinoma with Rare Epidermal Growth Factor Receptor Mutation G719X: a Case Report and Literature Review.

A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature

Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Uncommon EGFR Mutations in a Cohort of Chinese NSCLC Patients and Outcomes of First-Line EGFR-TKIs and Platinum-Based Chemotherapy.

A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and Its Response to EGFR-TKIs

A Novel Acquired EGFR-SEPT14 Fusion Confers Differential Drug Resistance to EGFR Inhibitors in Lung Adenocarcinoma.

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Mutations of the epidermal growth factor receptor gene in NSCLC patients.

Resistance to Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitors in a Patient with Transformation from Lung Adenocarcinoma to Small Cell Lung Cancer: A Case Report

EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

L858r-Positive Lung Adenocarcinoma with Kras G12v, Egfr T790m and Egfr L858r Mutations: A Case Report

P3.01-104 EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

Epidermal growth factor receptor mutations in lung cancer

EP1.14-46 the KIF5B-RET Fusion As a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma

The Predictive Value of Uncommon EGFR Mutation in Patients with Non-Small-cell Lung Cancer.

A Lung Adenocarcinoma with Rare Epidermal Growth Factor Receptor Exon 20 V774M Mutation Was Sensitive to Osimertinib: A Case Report and Molecular Structural Analysis